BROADCASTS.com

Vidcast:  https://youtu.be/gyHNlHNrOLc

From the actual documents the company submitted to the FDA and CDC.  The Moderna Vaccine consists of messenger RNA wrapped up in a lipid nanoparticle package.  The RNA is formulated to avoid immune destruction once injected and to code for a CoVid spike glycoprotein that will provoke production of a human antibody.  It is stored as a frozen suspension at -13 to 5 degrees Fahrenheit.   It is supplied in a 10 dose vial and is given as two 100 ug IM injections 28 days apart.   The vaccine does not contain eggs, preservatives, or latex.

It was first tested for safety and immunogenicity in a phase 1 trial of 120 persons and a fu phase 2 trial of 600 persons.  It’s effectiveness was confirmed and safety checked in a randomized blinded phase 3 trial involving 30,000 participants.  

The results showed an ability to prevent any CoVid infection for all age patients of 94%, for those 18-64 yrs of 96%, and for those 65 and older of 86%.  No severe or fatal CoVid cases occurred in those vaccinated.  Vaccine efficiency for those receiving only one dose was 43%.  

The most common adverse local reaction was injection site pain in 88 to 90%.  Swelling of armpit lymph noses occurred in 12% to 16%.

The 3 most common systemic adverse response were fatigue 68%, headache in 63%, muscle aches in 60%, joint pain in 45%, chills in 43%, and fever in 15%.

Though its overall effectiveness appears to be reduced for some new CoVid strains, it almost certainly will prevent severe CoVid infections and death due to these as well as due to the original CoVid strain.   Get vaccinated!

https://www.fda.gov/media/144434/download

https://www.fda.gov/media/144673/download

#moderna #vaccine #CoVid